Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys 898 Shares of Haemonetics Corporation $HAE

Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in Haemonetics Corporation (NYSE:HAE) by 7.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,907 shares of the medical instruments supplier’s stock after buying an additional 898 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Haemonetics were worth $963,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey lifted its holdings in Haemonetics by 6.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 11,400 shares of the medical instruments supplier’s stock worth $851,000 after purchasing an additional 709 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Haemonetics by 1.9% in the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after purchasing an additional 23,257 shares during the period. Boston Partners lifted its stake in shares of Haemonetics by 2.2% in the second quarter. Boston Partners now owns 543,169 shares of the medical instruments supplier’s stock worth $40,660,000 after buying an additional 11,738 shares during the last quarter. Zions Bancorporation National Association UT boosted its holdings in shares of Haemonetics by 8.0% during the 2nd quarter. Zions Bancorporation National Association UT now owns 46,621 shares of the medical instruments supplier’s stock worth $3,478,000 after buying an additional 3,447 shares during the period. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Haemonetics by 11.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 152 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

HAE has been the topic of several recent analyst reports. Raymond James Financial reiterated an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a report on Friday, November 14th. Barrington Research lifted their price objective on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Mizuho lowered their target price on Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Finally, Citigroup dropped their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.70.

Haemonetics Stock Up 5.0%

NYSE HAE opened at $78.89 on Monday. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $89.69. The stock has a market cap of $3.69 billion, a PE ratio of 24.13, a PEG ratio of 0.91 and a beta of 0.43. The firm has a 50-day simple moving average of $55.60 and a 200 day simple moving average of $62.90. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter in the prior year, the firm posted $1.12 EPS. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.